Drug Information

General Information
Drug ID
DR00168
Drug Name
Latanoprost
Synonyms
AR-202; Catioprost; Isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinor-prost-5-en-1-oate; Isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinorprost-5-en-1-oate; Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate; L1167_SIGMA; Latanoprost (JAN/USAN/INN); Latanoprost free acid; Nova-21027; PHXA-41; PhXA34 [as 15(R,S)-isomer]; PhXA41; Propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate; Propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate; XA-41; XA41; Xalatan; Xalatan (TN)
Drug Type
Small molecular drug
Indication Ocular hypertension [ICD11:9C61.01] Approved [1]
Open angle glaucoma [ICD11:9C61] Approved [1]
Therapeutic Class
Antihypertensive Agents
Structure
3D MOL 2D MOL
Formula
C23H34O5
Canonical SMILES
C1C(C(C(C1O)CC=CCCCC(=O)O)CCC(CCC2=CC=CC=C2)O)O
InChI
InChI=1S/C23H34O5/c24-18(13-12-17-8-4-3-5-9-17)14-15-20-19(21(25)16-22(20)26)10-6-1-2-7-11-23(27)28/h1,3-6,8-9,18-22,24-26H,2,7,10-16H2,(H,27,28)/b6-1-/t18-,19+,20+,21-,22+/m0/s1
InChIKey
HNPFPERDNWXAGS-NFVOFSAMSA-N
CAS Number
CAS 130209-82-4
Pharmaceutical Properties Molecular Weight 390.5 Topological Polar Surface Area 98
Heavy Atom Count 28 Rotatable Bond Count 12
Hydrogen Bond Donor Count 4 Hydrogen Bond Acceptor Count 5
XLogP
3.1
PubChem CID
6441636
PubChem SID
103286196 ,114563873 ,118842177 ,11968815 ,135124962 ,135611159 ,135650508 ,142805251 ,14829941 ,164228148 ,198989236 ,224405006 ,227536373 ,241078678 ,24724524 ,252421418 ,252457330 ,252562137 ,29217578 ,43034285 ,56311305 ,57369233 ,75823169
ChEBI ID
ChEBI:6384
TTD Drug ID
D0C6NM
DT(s) Transporting This Drug OATP2A1 Transporter Info Organic anion transporting polypeptide 2A1 Substrate [2]
OATP2B1 Transporter Info Organic anion transporting polypeptide 2B1 Substrate [2]
References
1 Latanoprost was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost. Invest Ophthalmol Vis Sci. 2010 May;51(5):2504-11.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.